Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT‐based radiomics signature

BACKGROUND: Tumor mutation burden (TMB) is an important determinant and biomarker for response of targeted therapy and prognosis in patients with lung cancer. The present study aimed to determine whether radiomics signature could non‐invasively predict the TMB status and driver mutations in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiaoxiao, Kong, Cheng, Xu, Weizhang, Yang, Sheng, Shi, Dan, Zhang, Jingyuan, Du, Mulong, Wang, Siwei, Bai, Yongkang, Zhang, Te, Chen, Zeng, Ma, Zhifei, Wang, Jie, Dong, Gaochao, Sun, Mengting, Yin, Rong, Chen, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775017/
https://www.ncbi.nlm.nih.gov/pubmed/31414580
http://dx.doi.org/10.1111/1759-7714.13163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775017/
https://www.ncbi.nlm.nih.gov/pubmed/31414580
http://dx.doi.org/10.1111/1759-7714.13163

Ejemplares similares